Experimental evidence indicates that pharmacological inhibitior of FATP2 abolishes neutrophil-mediated immunosuppressive activity, and its combination with immune checkpoint inhibitors (ICIs) effectively blocks tumor progression (Veglia et al., 2019). This evidence concerns the gene SLC27A2 and neoplasm.